Real-World Evidence Summit Europe 2025: Key Trends and Takeaways
The integration of Real-World Evidence (RWE) into healthcare decision-making is transforming how pharmaceutical companies approach Health Economics and Outcomes Research (HEOR), pricing, and reimbursement strategies. To delve into these advancements, the EVIDENCE 360: Real World Evidence, Pricing & Reimbursement Summit Europe is scheduled for 26th-27th May 2025 in Frankfurt, Germany.
Summit Overview
This two-day event is tailored for healthcare professionals, pharmaceutical leaders, policymakers, and researchers. It aims to explore the latest trends, challenges, and innovations in RWE, pricing strategies, and reimbursement frameworks within Europe. As the healthcare landscape evolves, RWE's role in decision-making becomes increasingly vital, influencing drug pricing, reimbursement, and integration into healthcare systems.
Key Topics:
The summit will address several critical areas:
Integration of RWE into Pricing Strategies: Examining how real-world data can inform and optimize pricing models.
Alignment with Health Technology Assessments (HTAs): Discussing the synchronization of RWE with HTAs to support evidence-based decisions.
Cross-Border Reimbursement Policies: Navigating the complexities of reimbursement across different European healthcare systems.
Advancements in Data Analytics: Exploring the impact of AI, machine learning, and big data on RWE analysis and application.
Patient-Centered Data Utilization: Incorporating patient-reported outcomes to address unmet needs and enhance healthcare access.
Why Attend?
Attendees will gain valuable insights into:
The latest RWE trends and their influence on pricing and reimbursement strategies in Europe.
The role of RWE in regulatory decision-making and its impact on HTAs.
The integration of digital health and AI in driving efficient reimbursement decisions.
Collaborative approaches to overcoming challenges in RWE integration and enhancing patient outcomes.
Target Audience
The summit is designed for:
Pharmaceutical and Biotech Executives: Involved in drug development, market access, and pricing strategies.
Regulators and Policymakers: From healthcare authorities and HTA agencies across Europe.
Researchers: Specializing in RWE to assess treatment outcomes and support regulatory submissions.
Advisors and Payers: Providing guidance on pricing strategies, reimbursement, and RWE implementation.
Investors: Interested in funding healthcare innovations, particularly in RWE and value-based pricing models.
Notable Speakers
The summit will feature industry experts such as:
Varun Gupta: Director, Value and Access, Novartis, Switzerland.
Gustavo Olivera: HEOR Expert, Sanofi, France.
Erwin Bruninx: Managing Director, GrayFox ComV.
James Graveston: Director, Real World Evidence Solutions, Whyze Health.
These speakers will share their insights on leveraging RWE for drug pricing and reimbursement, aligning with the themes of the RWE and Market Access Summit 2025.
For more information and to register for the summit at
https://veridonglobal.com/events/evidence-360-rwe-pricing-reimbursement-summit-europe/evidance-360-registration/
Engaging in this summit will provide attendees with the knowledge and connections necessary to navigate the evolving landscape of RWE and its application in HEOR, pricing, and reimbursement strategies.
Real-World Evidence Summit Europe 2025: Key Trends and Takeaways
The integration of Real-World Evidence (RWE) into healthcare decision-making is transforming how pharmaceutical companies approach Health Economics and Outcomes Research (HEOR), pricing, and reimbursement strategies. To delve into these advancements, the EVIDENCE 360: Real World Evidence, Pricing & Reimbursement Summit Europe is scheduled for 26th-27th May 2025 in Frankfurt, Germany.
Summit Overview
This two-day event is tailored for healthcare professionals, pharmaceutical leaders, policymakers, and researchers. It aims to explore the latest trends, challenges, and innovations in RWE, pricing strategies, and reimbursement frameworks within Europe. As the healthcare landscape evolves, RWE's role in decision-making becomes increasingly vital, influencing drug pricing, reimbursement, and integration into healthcare systems.
Key Topics:
The summit will address several critical areas:
Integration of RWE into Pricing Strategies: Examining how real-world data can inform and optimize pricing models.
Alignment with Health Technology Assessments (HTAs): Discussing the synchronization of RWE with HTAs to support evidence-based decisions.
Cross-Border Reimbursement Policies: Navigating the complexities of reimbursement across different European healthcare systems.
Advancements in Data Analytics: Exploring the impact of AI, machine learning, and big data on RWE analysis and application.
Patient-Centered Data Utilization: Incorporating patient-reported outcomes to address unmet needs and enhance healthcare access.
Why Attend?
Attendees will gain valuable insights into:
The latest RWE trends and their influence on pricing and reimbursement strategies in Europe.
The role of RWE in regulatory decision-making and its impact on HTAs.
The integration of digital health and AI in driving efficient reimbursement decisions.
Collaborative approaches to overcoming challenges in RWE integration and enhancing patient outcomes.
Target Audience
The summit is designed for:
Pharmaceutical and Biotech Executives: Involved in drug development, market access, and pricing strategies.
Regulators and Policymakers: From healthcare authorities and HTA agencies across Europe.
Researchers: Specializing in RWE to assess treatment outcomes and support regulatory submissions.
Advisors and Payers: Providing guidance on pricing strategies, reimbursement, and RWE implementation.
Investors: Interested in funding healthcare innovations, particularly in RWE and value-based pricing models.
Notable Speakers
The summit will feature industry experts such as:
Varun Gupta: Director, Value and Access, Novartis, Switzerland.
Gustavo Olivera: HEOR Expert, Sanofi, France.
Erwin Bruninx: Managing Director, GrayFox ComV.
James Graveston: Director, Real World Evidence Solutions, Whyze Health.
These speakers will share their insights on leveraging RWE for drug pricing and reimbursement, aligning with the themes of the RWE and Market Access Summit 2025.
For more information and to register for the summit at https://veridonglobal.com/events/evidence-360-rwe-pricing-reimbursement-summit-europe/evidance-360-registration/
Engaging in this summit will provide attendees with the knowledge and connections necessary to navigate the evolving landscape of RWE and its application in HEOR, pricing, and reimbursement strategies.